New TIEFENBACHER API website – part of the TIEFENBACHER GROUP Brand Relaunch

“We are very thrilled to officially announce our new TIEFENBACHER API website, representing the raw material business of TIEFENBACHER GROUP, and aiming to expand our role as a high-quality distributor for active pharmaceutical ingredients. Our new website communicates a clear message of who we are, what we rise for and where our value lies when delivering on our best value seal: BETTER ACCESS, BETTER QUALITY, and BETTER SUPPLY.

The new API Website is an important milestone within the international brand relaunch of our whole company group (www.tiefenbachergroup.com) and represents the fundamental changes which we have started in the recent years. We are on the move to drive important efficiencies in our supply chain and become a more and more innovative, patient-centered enterprise with a global pharmaceutical footprint.”

Sören Schlosser and Oliver Schrader, Managing Directors TIEFENBACHER API

“We are very thrilled to officially announce our new TIEFENBACHER API website, representing the raw material business of TIEFENBACHER GROUP, and aiming to expand our role as a high-quality distributor for active pharmaceutical ingredients. Our new website communicates a clear message of who we are, what we rise for and where our value lies when delivering on our best value seal: BETTER ACCESS, BETTER QUALITY, and BETTER SUPPLY.

The new API Website is an important milestone within the international brand relaunch of our whole company group (www.tiefenbachergroup.com) and represents the fundamental changes which we have started in the recent years. We are on the move to drive important efficiencies in our supply chain and become a more and more innovative, patient-centered enterprise with a global pharmaceutical footprint.”

Sören Schlosser and Oliver Schrader, Managing Directors TIEFENBACHER API


Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health

Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’ commitment to further develop and commercialize innovative products within individualized treatments and digital health, combining traditional drug-based medicines with digital therapeutics and intelligent dosing.